Mark John Lynch
Impact in
- Otorhinolaryngology top 0.1%
- Head and Neck Cancer Studies
- Hepatology top 0.2%
- Hepatocellular Carcinoma Treatment and Prognosis
Papers in
-
- Head and Neck Cancer Studies 10
- Oncology 18
- Cancer Immunotherapy and Biomarkers 13
- HER2/EGFR in Cancer Research 4
- Co-authors
- Scott M. Wilhelm (7 shared papers)Lila Adnane (3 shared papers)Augusto Villanueva (1 shared paper)Josep Maria Llovet (1 shared paper)Philippa H. Newell (1 shared paper)Dean P. Wilkie (3 shared papers)Angela McNabola (2 shared papers)Charles Chen (2 shared papers)
- Journals
- Cancer Research (5 papers)Blood (3 papers)Annals of Oncology (3 papers)Molecular Cancer Therapeutics (2 papers)British Journal of Haematology (2 papers)
- Partner nations
- United StatesJapanFrance
In The Last Decade
Mark John Lynch
58 papers receiving 15.9k citations
Mark John Lynch's Hit Papers
Peers
Comparison fields: 5 of 138
- Otorhinolaryngology 2.3k
- Hepatology 2.5k
- Oncology 4.6k
- Pulmonary and Respiratory Medicine 1.5k
- Molecular Biology 3k
Countries citing papers authored by Mark John Lynch
This map shows the geographic impact of Mark John Lynch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark John Lynch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark John Lynch more than expected).
Fields of papers citing papers by Mark John Lynch
This network shows the impact of papers produced by Mark John Lynch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark John Lynch. The network helps show where Mark John Lynch may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark John Lynch, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 59 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck Hit paper breakdown → | 2016 | 4071 |
| 2 | BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis Hit paper breakdown → | 2004 | 3506 |
| 3 | Discovery and development of sorafenib: a multikinase inhibitor for treating cancer Hit paper breakdown → | 2006 | 1558 |
| 4 | Sorafenib Blocks the RAF/MEK/ERK Pathway, Inhibits Tumor Angiogenesis, and Induces Tumor Cell Apoptosis in Hepatocellular Carcinoma Model PLC/PRF/5 Hit paper breakdown → | 2006 | 1341 |
| 5 | Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling Hit paper breakdown → | 2008 | 1242 |
| 6 | Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity Hit paper breakdown → | 2010 | 1138 |
| 7 | Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression Hit paper breakdown → | 2018 | 640 |
| 8 | 2006 | 410 | |
| 9 | Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial Hit paper breakdown → | 2017 | 349 |
| 10 | 2016 | 196 | |
| 11 | 2011 | 166 | |
| 12 | 1988 | 163 | |
| 13 | 2007 | 147 | |
| 14 | 2019 | 132 | |
| 15 | Preclinical antitumor activity of BMS-214662, a highly apoptotic and novel farnesyltransferase inhibitor. | 2001 | 99 |
| 16 | 2018 | 83 | |
| 17 | 2019 | 83 | |
| 18 | 2017 | 82 | |
| 19 | 2003 | 79 | |
| 20 | 1995 | 67 |
About Mark John Lynch
Mark John Lynch is a scholar working on Otorhinolaryngology, Oncology, Hematology, Molecular Biology and Pathology and Forensic Medicine, having authored 59 papers that have together received 16.3k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (13 papers), Head and Neck Cancer Studies (10 papers), Multiple Myeloma Research and Treatments (7 papers), Angiogenesis and VEGF in Cancer (5 papers), TGF-β signaling in diseases (4 papers), HER2/EGFR in Cancer Research (4 papers), Clostridium difficile and Clostridium perfringens research (3 papers) and Protein Kinase Regulation and GTPase Signaling (3 papers). The work is most often cited by research in Otorhinolaryngology (2.3k citations), Hepatology (2.5k citations), Oncology (4.6k citations), Pulmonary and Respiratory Medicine (1.5k citations) and Molecular Biology (3k citations). Mark John Lynch has collaborated with scholars based in United States, Japan and France. Frequent co-authors include Scott M. Wilhelm, Lila Adnane, Augusto Villanueva, Josep Maria Llovet, Philippa H. Newell, Dean P. Wilkie, Angela McNabola, Charles Chen, Susan L. Kelley and Roger A. Smith. Their work appears in journals such as Cancer Research, Blood, Annals of Oncology, Molecular Cancer Therapeutics and British Journal of Haematology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.